X4 PHARMACEUTICALS, INC Weighted Average Number of Shares Outstanding, Basic and Diluted
X4 PHARMACEUTICALS, INC (XFOR) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 35.44 million shares for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-08-04
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-06-30 was 35.44M shares, a 33.59% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 33.74M shares, a 62.58% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 29.00M shares, a 43.52% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 26.61M shares, a 32.48% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 25.75M shares, a 28.25% increase from fiscal 2020.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 20.08M shares, a 74.13% increase from fiscal 2019.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 11.53M shares, a 2411.98% increase from fiscal 2018.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 459.00K shares, a 0.22% increase from fiscal 2017.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | 35.44M shares 10-Q · filed 2022-08-04 | 34.59M shares 10-Q · filed 2022-08-04 | 32.72M shares derived: average of 3 quarters · filed 2022-08-04 | 31.19M shares derived: average of 4 quarters · filed 2022-08-04 | ||||
| 2022-03-31 | 33.74M shares 10-Q · filed 2022-05-12 | 31.37M shares derived: average of 2 quarters · filed 2022-05-12 | 29.78M shares derived: average of 3 quarters · filed 2022-05-12 | 28.97M shares derived: average of 4 quarters · filed 2022-08-04 | ||||
| 2021-12-31 | 29.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 27.80M shares derived: average of 2 quarters · filed 2022-03-17 | 27.38M shares derived: average of 3 quarters · filed 2022-08-04 | 25.75M shares 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | 26.61M shares 10-Q · filed 2021-11-04 | 26.57M shares derived: average of 2 quarters · filed 2022-08-04 | 24.67M shares 10-Q · filed 2021-11-04 | 23.52M shares derived: average of 4 quarters · filed 2022-08-04 | ||||
| 2021-06-30 | 26.53M shares 10-Q · filed 2022-08-04 | 23.66M shares 10-Q · filed 2022-08-04 | 22.49M shares derived: average of 3 quarters · filed 2022-08-04 | 21.89M shares derived: average of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | 20.75M shares 10-Q · filed 2022-05-12 | 20.48M shares derived: average of 2 quarters · filed 2022-05-12 | 20.35M shares derived: average of 3 quarters · filed 2022-05-12 | 20.27M shares derived: average of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | 20.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 20.14M shares derived: average of 2 quarters · filed 2022-03-17 | 20.11M shares derived: average of 3 quarters · filed 2022-03-17 | 20.08M shares 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | 20.09M shares 10-Q · filed 2021-11-04 | 20.06M shares derived: average of 2 quarters · filed 2021-11-04 | 20.04M shares 10-Q · filed 2021-11-04 | 19.16M shares derived: average of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | 20.03M shares 10-Q · filed 2021-08-03 | 20.02M shares 10-Q · filed 2021-08-03 | 18.86M shares derived: average of 3 quarters · filed 2022-03-17 | 17.78M shares derived: average of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | 20.01M shares 10-Q · filed 2021-05-06 | 18.27M shares derived: average of 2 quarters · filed 2022-03-17 | 17.03M shares derived: average of 3 quarters · filed 2022-03-17 | 16.07M shares derived: average of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | 16.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 15.54M shares derived: average of 2 quarters · filed 2022-03-17 | 14.75M shares derived: average of 3 quarters · filed 2022-03-17 | 11.53M shares 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | 14.56M shares 10-Q · filed 2020-11-05 | 13.87M shares derived: average of 2 quarters · filed 2020-11-05 | 9.87M shares 10-Q · filed 2020-11-05 | 7.48M shares derived: average of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | 13.18M shares 10-Q · filed 2020-08-04 | 13.18M shares 10-Q · filed 2019-08-07 | 7.48M shares 10-Q · filed 2020-08-04 | 7.48M shares 10-Q · filed 2019-08-07 | 5.12M shares derived: average of 3 quarters · filed 2021-03-19 | 3.95M shares derived: average of 4 quarters · filed 2021-03-19 | ||
| 2019-03-31 | 1.72M shares 10-Q · filed 2020-05-07 | 1.72M shares 10-Q · filed 2019-05-15 | 1.09M shares derived: average of 2 quarters · filed 2021-03-19 | 878.67K shares derived: average of 3 quarters · filed 2021-03-19 | 773.68K shares derived: average of 4 quarters · filed 2021-03-19 | |||
| 2018-12-31 | 459.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 459.00K shares derived: average of 2 quarters · filed 2021-03-19 | 458.91K shares derived: average of 3 quarters · filed 2021-03-19 | 459.00K shares 10-K · filed 2021-03-19 | 14.31M shares 10-K · filed 2019-03-11 | |||
| 2018-09-30 | 459.00K shares 10-Q · filed 2019-11-07 | 14.32M shares 10-Q · filed 2018-11-09 | 458.86K shares derived: average of 2 quarters · filed 2019-11-07 | 459.00K shares 10-Q · filed 2019-11-07 | 14.30M shares 10-Q · filed 2018-11-09 | 416.50K shares derived: average of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | 458.72K shares 10-Q · filed 2019-08-07 | 14.30M shares 10-Q · filed 2018-08-13 | 458.35K shares 10-Q · filed 2019-08-07 | 14.30M shares 10-Q · filed 2018-08-13 | 402.33K shares derived: average of 3 quarters · filed 2020-03-12 | 430.22K shares derived: average of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | 457.97K shares 10-Q · filed 2019-05-15 | 14.29M shares 10-Q · filed 2018-05-10 | 374.14K shares derived: average of 2 quarters · filed 2020-03-12 | 420.72K shares derived: average of 3 quarters · filed 2020-03-12 | 444.02K shares derived: average of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | 290.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 402.10K shares derived: average of 2 quarters · filed 2020-03-12 | 439.37K shares derived: average of 3 quarters · filed 2020-03-12 | 458.00K shares 10-K · filed 2020-03-12 | 2.06M shares 10-K · filed 2019-03-11 | |||
| 2017-09-30 | 513.90K shares 10-Q · filed 2018-11-09 | 513.90K shares derived: average of 2 quarters · filed 2018-11-09 | 513.90K shares 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | 513.90K shares 10-Q · filed 2018-08-13 | 513.90K shares 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | 513.90K shares 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | 513.53K shares 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |